Antigestational effects of *Icon*, a pyrethroid insecticide on mid pregnancy of rats

*W. D. Ratnasooriya*, S. S. K. Ratnayake, Y. N. A. Jayatunga

The Ceylon Journal of Medical Science 2004; 47:17-28

Abstract

*Icon* is a water miscible type II synthetic pyrethroid insecticide based on active ingredient lambda cyhalothrin (10% w/v). It was recently introduced to Sri Lanka as an indoor spray against malaria vector mosquitoes. The aim of this study was to ascertain the potential effects of *Icon* on pregnancy outcome of rats when exposed during mid pregnancy (days 8–14). *Icon* was orally administered daily during this period in three different doses: 63, 83, 125 mg/kg body wt./day of *Icon* (active ingredient; lambda cyhalothrin; 6.3, 8.3, 12.5 mg/kg/day) respectively. Several parameters of reproduction, pre- and post-natal development were monitored. The results demonstrated that *Icon* is detrimental to pregnancy outcome (in terms of number of uterine implants, number of viable implants, post implantation loss, number of pups born, litter index, and foetal survival ratio) but induced no changes in gestational length, gross morphological birth abnormalities or detectable pre- and post-natal developmental impairments. The anti-reproductive effects of *Icon* were mediated by multiple mechanisms (hypophagia, maternal toxicity, stress, uterine myotropic activity, embryotoxicity, anti-progestogenic activity, inhibition of decidualization process, abortifacient activity and vaginal bleeding) leading to enhancement of post-implantation losses. It is concluded that exposure to *Icon* during mid gestation poses a considerable threat to pregnancy of rats.

Key words: *Icon*, Insecticide, lambda cyhalothrin, pyrethroids, pregnancy, mid gestation, post-implantation loss, reproduction

Introduction

*Icon*, produced by the Public Health Division of the Imperial Chemical Industries in England (currently known as Zeneca) is a water miscible type II synthetic pyrethroid insecticide having lambda-cyhalothrin (10% w/v) as the active ingredient. Information on inert fillers, adjuvants, excipient, wetting agents and purity are not available. This insecticide was recently introduced to Sri Lanka to use as an indoor spray against malaria vector mosquitoes. *Icon* is a contact and residual insecticide and acts as a neuropoison by interfering with the conductance of nerve...
membrane by prolonging the sodium current (2, 3). Pyrethroids are also known to increase spontaneous release of neurotransmitters such as GABA, dopamine and noradrenaline, and also act as a hormone disruptor (4, 5).

The effective spray dose of Icon® in Sri Lanka is 312 mg/m² (CIC brochure and personal communication K. Gunasekara, Parasitologist, Anti Malaria Campaign, Sri Lanka,). Insecticide residues in indoor environments are more persistent than in the environment at large, as indoors residues are not subjected to degradation by sun, rain and soil microbes and hence there is a potential risk that inhabitants in Icon®-sprayed houses are continually subjected to dietary, respiratory and cutaneous exposures (2).

Recently we showed that Icon® exposure to male rats impaired sexual competence (6) and in female rats when exposed during early gestation was detrimental to their pregnancy outcome (7). Several pesticides when exposed during mid pregnancy are known to interrupt pregnancy (8, 9, 10, 11, and 12). However, the potential anti-reproductive effects of Icon® when exposed during mid pregnancy is not known and this is worth examining as Icon® is an endocrine disruptor (7).

The aim of this study was to investigate the effects of Icon® on reproductive outcome of female rats subjected to repeated exposure during mid pregnancy. This was done using doses of Icon® (approximately 2.5 to 4 times lower than the recommended spray dose in Sri Lanka) identical to what has been used to ascertain reproductive effects when exposed during early pregnancy (7).

**Material and Methods**

**Animals**

Healthy adult cross bred female rats (weight: 200–250 g) and male rats (weight: 200–250 g) of proven fertility from the colony maintained at the Department of Zoology, University of Colombo were used. They were maintained singly in plastic cages under standardized animal house conditions (temperature: 28–30 °C; photoperiod: approximately 12 h light/12 h dark; and relative humidity: 50–55 %) with free access to pelleted food (Master Feeds Lanka Ltd., Colombo, Sri Lanka) and tap water. Except at the time of experiment the animals were handled only during cage cleaning.

**Icon® preparation**

Icon® was obtained from Anti-Malaria Campaign, Narahenpitiya, Colombo 5, Sri Lanka. Three doses [63 (low), 83 (mid) and 125 (high) mg/kg/day; (containing active ingredient lambda cyhalothrin 6.3, 8.3, 12.5 mg /kg/day respectively)] of Icon® in 1ml aliquots were prepared by mixing Icon® in distilled water (DW). These doses are comparable to what has been used previously by us to investigate the potential reproductive effects on male rats (6) and identical to what has been used to test the anti-reproductive effects on female rats when exposed during early pregnancy (7).

**Icon® administration**

Icon® or vehicle (DW) was orally administered by gastric intubation (09.00 – 10.00 h) from days 8-14 of pregnancy. The rats were made pregnant by individually pairing pro-oestrous females overnight with a male rat. Vaginal smears were examined on the following morning (08.00–09.00h).
for presence of spermatozoa (considered as day 1 of pregnancy).

**Adverse effects**

Following every dosing, cage side observations were made on each rat continuously for 3–5 h for mortality, overt signs of toxicity (salivation, lacrimation, ptosis, squinted eyes, wilting, tremors, convulsions, ataxia, yellowing and loss of fur), stress (exophthalmia, erection of fur), lethargy (reduction of spontaneous walking movements, climbing in cage, cleaning of fur) recumbence, aversive behaviours (self biting and scratching, licking of tail and/or paw, intense self grooming behaviour and vocalization), diarrhoea, colour and odour of urine and vaginal bleeding. In addition, the rectal temperature was recorded on day 8 of pregnancy before dosing and on day 14 of pregnancy (5 h after dosing) using a clinical thermometer (Oson Duopris Company Ltd., Berlin, Germany).

**Effect on food and water intake**

Food and water intake of Icon® treated rats [low (n = 12), mid (n = 12), high (n = 9)] or control (n = 12) were determined daily from days 8-14 of treatment using conventional laboratory techniques (13).

**Effect on body weight**

The body weights of Icon® treated rats [low (n = 12), mid (n = 12), high (n = 9)] or control (n = 12) were determined 5 h after dosing on days 8 and 14 of pregnancy using an electronic balance (MP6000, Chyo YMC & Corporation Ltd., Japan).

**Effect on haematology**

On day 1 post-treatment [low (n = 12), mid (n = 12), high (n = 9) or control (n = 12)], blood was collected from tails under aseptic conditions and red blood cell (RBC) counts, white blood cell (WBC) counts, differential leukocyte (DC) counts, packed cell volume (PCV) and haemoglobin content were estimated as described by Cheesbrough et. al., (14). The mean corpuscular haemoglobin concentration (MCHC) and mean corpuscular volume (MCV) were then computed.

**Evaluation of sedative potential**

The sedative potential of Icon® was evaluated using the rat hole-board technique (15). Forty-five, day 8 pregnant rats were assigned into 4 groups and orally treated with Icon® [low (n = 12), mid (n = 12), high (n = 9)] or vehicle (n = 12) for 7 consecutive days. Five hours after the last dosing, rats were individually placed on the centre of the rat hole-board and were given 7.5 min trial periods. During this period the number of head dips, rears and locomotory activity were noted.

**Effect on righting reflex**

The time for righting reflex on rats used in evaluating the sedative potential were determined 2 h prior to treatment and immediately after hole-board test as described by Mortin et. al., (16).

**Effect on pregnancy outcome and pre- and post-natal development of pups**

Forty-five, day 8 pregnant rats were assigned into 4 groups and orally administered with either different doses of Icon® [low (n = 12), mid (n = 12), high (n = 12)] or vehicle (n = 12) for 7 consecutive days.

On day 17 of pregnancy, these rats were subjected to a laparotomy under mild ether
anesthesia with aseptic precautions. Upon laparotomy, the total number of uterine implants, the number of viable implants (with pulsating blood vessels and reddish appearance), and the number of dead implants (with non pulsating blood vessels and bluish appearance) were recorded. The appearance and number of corpora lutea in ovaries were also noted. Furthermore, the distribution of embryos in the uterine horns, and the diameter of the first embryo at the ovarian end were measured using a vernier caliper (Gallenkamp, Loughborough, UK). Subsequently the laparotomy incision was sutured. Tetracycline ointment (Wockhardt Veterinary Ltd., Bombay, India) was applied and was injected with a subcutaneous dose of 0.1 ml tetracycline (Wockhardt Veterinary Ltd., Bombay, India). Then the animals were allowed to recover and deliver. The gestation length was recorded.

After delivery, on postnatal day 1, the pups were closely observed and the total number of pups, the total number of viable pups, their body weights (using an electronic balance), cranial length, cranial diameter, cranio-sacral length and tail length of each pup (using a vernier caliper) were determined. The presence of gross external congenital abnormalities were also noted (amelia, anomaly of tail, clubfoot, oligodactyly or syndactyly). Then the pups were observed once daily for the appearance of fur and opening of eyes. The following reproductive indices were computed using the reproductive findings.

Post-implantation loss (%) = [(# implants - # viable implants) / # implants x 100; Gestation index= (# live litter / # pregnant) x 100; Litter index (%) = (# littered pups / # implants) x 100; Live birth index (%) = (# viable pups / # littered pups) x 100; Foetal survival ratio (%) = (# surviving pups / # implants) x 100; Viability index (%) = (# day 1 surviving animals / # live pups per animal) x 100].

Statistical analysis

Data are expressed as means ± standard error of mean (SEM). Mann-Whitney U-test and G-test were used as appropriate. P < 0.05 was considered as statistically significant.

Results

Adverse effects

No deaths were recorded in any of the treated rats. Further, none of the treated rats showed, lacrymation, ptosis, squinted eyes, wilting, tremors, convulsions, yellowing and marked loss of fur, and aversive behaviours.

As shown in the Table 1, Icon® produced ataxia, exophthalmia, piloerection, salivation (low dose: around facial region; mid dose: neck region; and high dose: almost throughout the entire body), vaginal bleeding (between days 9–12 of pregnancy), diarrohea (between days 9–14 of pregnancy) and pale yellow (low dose) to dark yellow (mid dose and high dose) coloured urine with an odour similar to that of Icon® between days 8–14 of pregnancy. These toxic effects were evident from 30–60 min. of administration of Icon® and were completely abolished on the following morning except with the high dose where the effects lasted for 2 days after the full treatment course. Icon® administration did not significantly alter the rectal temperature of any treated rats (P > 0.05; Mann-Whitney U-test).
Effect on food and water intake
The highest dose of Icon® induced a significant impairment in food consumption from days 3–7 of treatment (P<0.05; Mann-Whitney U-test). In contrast, there was no significant inhibition of water intake in any of the Icon® treated rats (P >0.05; Mann-Whitney U-test, data not shown).

Effect on body weight
Body weight gain was significantly impaired by Icon®, low (by 60%), mid (by 101%) and high (by 196%): weight gain of control, low, mid and high dose groups respectively being 12.9 ± 2.1, 5.1 ± 2.5, -0.1 ± 2.2 and -12.4 ± 4.1 g (P<0.05; Mann-Whitney U-test).

Haematology
Of the haematological variables investigated both mid (by 39%) and high (by 72%) doses of Icon® significantly increased the WBC count (control vs. mid vs. high dose: 1.8 ± 0.1 vs. 2.5 ± 0.1 vs. 3.1 ± 0.2 x 10³/mm³). The highest dose also significantly increased the PCV (by 10%) (control vs. high dose: 40.6 ± 0.7 vs. 44.7 ± 0.7 %) and MCV (by 15%) (control vs. high dose: 44.6 ± 1.7 vs. 51.4 ± 2.3 ) (P<0.05; Mann-Whitney U-test).

Sedative effects
None of the three doses of Icon® significantly impaired any of the variables investigated (data not shown) (P>0.05; Mann-Whitney U-test).

Righting reflex
Only the highest dose of Icon® significantly enhanced the righting reflex time (P>0.05; Mann-Whitney U-test) (data not shown).

Reproductive outcome, pre- and post-natal development of pups
The results obtained are summarized in Tables 2 and 3. All treated rats had normal numbers of reddish, rounded, seemingly healthy looking corpora lutea. The low dose of Icon® when administered between days 8–14 of pregnancy had no significant effect on any of the variables investigated. In contrast, the mid dose significantly impaired the number of uterine implants (by 28%), the number of viable implants (by 37%), the number of pups born (by 37%), the number of live pups born (by 40%), the litter index (by 44%), and the foetal survival ratio (by 34%). Further, these anti-reproductive effects were accompanied by a marked and significant increase of post-implantation losses (mid dose by 82% and high dose by 1512%). In contrast, with the high dose of Icon®, no uterine implants were seen with a 100% post-implantation loss. Because of this the other variables listed could not be investigated.

The pups born with both low and mid doses of Icon® appeared normal with no gross external abnormalities. None of the pre- and post-natal developmental variables investigated were significantly altered both by the low and mid doses of Icon® (Table 3).

Discussion
This study examined the anti-gestational effects of Icon® when exposed orally during mid pregnancy of rats (days 8–14). The results demonstrated that, in rats, repeated oral exposure of Icon® during mid gestation is detrimental to pregnancy outcome (in terms of the number of uterine implants, number of viable implants, post
implantation loss, number of pups born, litter index and foetal survival ratio). Previous experiments have shown that exposure of rats to Icon® during early pregnancy does not produce any impairment in pre- and post-natal development of pups or gross birth defects (7). Still we cannot completely rule out any Icon®-induced minor and subtle effects on embryo/foetotoxicity and pup development. In contrast, both teratogenic and developmental retardation have been reported with some pyrethroid (9, 17, 18), carbamate (10, 11), organophosphate (12) and organochlorine (19) insecticides following mid pregnancy exposure.

It is generally accepted that pregnancy disruption by reproductive toxicants are mediated by different mechanisms (20, 21). This seems to be the case with the current study as well. The main mechanism of Icon®-induced disruption of mid pregnancy is due to a marked potentiation of post-implantation loss. On the other hand, Icon® exposure during early gestation is known to interrupt pregnancy both by increased pre- and post-implantation losses (7). In the rat, uterine implantation occurs on day 4 of pregnancy (22). Hence, pre-implantation loss cannot account for any of the anti-reproductive effects seen in this study.

Non-specific and specific mechanisms can potentiate post-implantation loss. Impairment of food intake and maternal weight loss (23) are two of the non-specific factors. In this study, Icon® induced maternal weight loss is likely to contribute to the observed anti-gestational effects. Several maternal toxicants interrupt pregnancy (20, 21) and this mode of action is also likely to be operative here as marked toxic signs were evident (ataxia, salivation, exophthalmia, piloerection, depressed body weights, food consumption, production of dark yellow coloured urine and diarrhoea). Stress is another non-specific mechanism that can induce post-implantation losses (24). In rats, stress inhibits luteal function during mid pregnancy causing foetal resorption (25). In this study the Icon® treated rats showed features of stress such as piloerection, exophthalmia and this may have contributed to foetal resorption. Other Investigators have also shown pyrethroid insecticides like cypermethrine (26) and carbamate insecticides like carbofuran (8) to be producing stress, particularly in mid pregnancy period. Further, we have previously shown increased adrenal weights and enlargement of zona fasciculata of adrenal cortex following Icon® treatment (7). Thus, it is likely that stress has played an important role in Icon®-induced pregnancy impairment which was seen in this study.

Sedatives are known to interrupt pregnancy (27). Such a mode of action is unlikely in this study as none of the variables of the rat-hole board technique were inhibited: a reliable and a sensitive test used widely to evaluate potential sedatives (15).

A specific mechanism that could increase post-implantation losses in this study is by a direct embryo/foetocidal action of Icon®. A marked loss of viability of foetuses (as judged by lack of pulsations in vitelline vessels and presence of dark blue uterine implants at laparotomy) with mid dose and a total lack of foetuses was seen with the high dose. Further, Icon® has been shown to kill both human spermatozoa and Artemia nauplii in vitro (7), which provide additional...
support to the above mechanism. Further, maternal toxic agents consumed during pregnancy are claimed to be embryo/foetocidal (24) and also several insecticides are known to possess embryo/foetocide activities (8, 10, 12).

In this study, both mid and the high doses of Icon® induced moderate to severe vaginal bleeding which was not accompanied with preterm delivery or pups born small for gestational age. However, shortening (28) and prolongation (8, 29) of gestation durations are reported with some pesticides. In contrast, no vaginal bleeding had been reported during early pregnancy of rats following Icon® exposure (7) but it did not result in a pre-term delivery or pups born small for gestational age.

Death of foetus in this study may also result from prolonged uterine contractions due to direct myotropic action of Icon® on uterine smooth muscle (7) or by an impairment of progesterone release and or progesterone antagonist activity (30). Indeed, we have previously shown that Icon® induced both tonic and phasic contractions in isolated rat uterine preparations (7) and that it has antiprogestogenic actions (7). An impairment of progesterone release may result due to stress (25) or due to negative effects of hypophagia and weight loss on the generation of GnRH pulses (31).

Foetal deaths could occur with Icon® by these mechanisms also. Progesterone/oestradiol ratio plays a crucial role in maintaining viability of embryos (32). Although Icon® is not oestrogenic it is anti-progestogenic (7) and this effect could alter the ratio and make the uterine environment hostile to embryos, leading to their deaths.

This study, together with our previous investigations (7) shows that repeated oral exposure of Icon® during both early and mid gestation is detrimental to pregnancy outcome in rats, but induced no detectable gross developmental defects. Icon® being an indoor spray, the pregnant domestic animals are liable to get affected.

Acknowledgements

We wish to thank Ms. Anoma De Silva for technical assistance

References

1. Icon - Public health insecticides - Technical Profile. Imperial Chemical Industries PLC: London, 1989.

2. International Programme on Chemical Safety (IPCS). Environmental Health Criteria 99. Cyhalothrin. World Health Organization: Geneva, 1990.

3. Integrated Risk Information System (IRIS). Cyhalothrin. US Environmental Protection Agency. National Library of Medicine: Toxnet database, 1995.

4. Clark J.M., Insecticides as tools in probing vital receptors and enzymes in excitable membranes. Pesticide Biochemistry and Physiology 1997; 57: 235 - 254.

5. Garey J., Wolff M.S., Estrogenic and antiprogestogenic activities of pyrethroid insecticide. Biochemical Biophysical Research Communication 1998; 251: 855 - 859.

6. Ratnasooriya W.D., Ratnayake S.S.K., Jayatunga Y.N.A., Effect of pyrethroid insecticide Icon® (Lambda cyhalothrin)
on reproductive competence of male rats. Asian Journal of Andrology 2002; 4: 35 – 41.

7. Ratnasooriya W.D., Ratnayake S.S.K., Jayatunga Y.N.A. Effect of Icon®, a pyrethroid insecticide on early pregnancy of rats. Human and Experimental Toxicology 2003; 22: 523 -533.

8. Jayatunga Y.N.A., Dangalle C.D., Ratnasoooriya W.D., Effects of mid term exposure to carbofuran on pregnancy outcome of female rats. Medical Science Research 1998; 26 : 679 – 683.

9. Abdel-Khalik M.M., Hanafy M.S.M., Abdel-Aziz M.I., Studies on the teratogenic effects of deltamethrin in rats. DTW (Dtsch Tierarztl Wochenschr) 1993; 100 : 142-143.

10. Cummings A.M., Harris S.T., Rehnberg G.L., Effects of methyl benzimidazole carbamate during early pregnancy in rats. Fundamentals of Applied Toxicology 1990; 15 : 528 – 535.

11. Mathur A., Bhatnagar P.A., Teratogenic study of carbaryl in Swiss albino mice. Food chemical toxicology 1991; 29 :629 –632.

12. Sircar S., Lahiri P., Lindane (gamma – HCH) causes reproductive failure and fetotoxicity in mice. Toxicology 1989; 59 : 171 –178.

13. Staff of UFAW. The UFAW handbook on the care and management of laboratory animals. E and S Livingston Ltd: Edinburgh, 1966.

14. Cheesbrough M., Mc Arther J., A Laboratory Manual for Rural Tropical Hospitals. Churchill Livingston: New York, 1976.

15. File S.E., Wardill A., Validity of head dipping as a measure of exploration in modified hole–board. Psychopharmacology 1975 ; 44: 53 – 57.

16. Mortin W.J., Lai N.K., Patriott S.L., Tsou K., Walter J.M., Antinociceptive actions of cannabinoids following intraverticular administration in rats. Brain Research 1993; 629 : 300– 304.

17. Husain R., Seth P.K., Neurotoxic effects of deltamethrin, a synthetic pyrethroid during early development in rats. International Journal of Toxicology 1991; 1 : 138.

18. da Silva G.M., Bernardi M.M., de Souza S.H., Pyrethroid insecticides and pregnancy : Effect on physical and behavioural development of rats. Veterinary and Human Toxicology 1991; 33: 315 – 317.

19. Vergieva T, Embryotoxicity and teratogenicity of pesticides. Proceedings; Toxicology of pesticides, European Coorperation on Environmental health aspects of the control of chemicals 1982 ; 9 : 67 -77.

20. Watterson A., Pesticides and reproduction. Pesticide News 1999; 44: 4 -12.
21. Anonymous. Are pesticides hazardous to our health. Journal of Pesticide Reform 1999; 19: 4 – 5.

22. Croxatto H., Physiology of gamete and embryo transport. Reproductive Biomedicinal Online 2002; 4: 160 – 169.

23. Wade G.N., Schneider J.E., Metabolic fuels and reproduction in female mammals. Neuroscience Behavioural Research 1992; 16: 235 – 272.

24. Mattison D.R., Tomford P.J., The mechanism of the action of reproductive toxicants. Toxicological Pathology 1989; 17: 346 – 376.

25. Sugino N., Nakamura Y., Okuno N., Shimamura K., Teyama T., Ishimatsu M., Kato H., Effect of restraint stress on luteal function in rats during mid pregnancy. Journal of Reproduction and Fertility 1994: 101: 23 –26.

26. Varshneya C., Singh T., Sharma L.D., Bahga H.S., Garg S.K. Immunotoxic responses of cypermethrin, a synthetic pyrethroid insecticide in rats. Indian Journal of Physiology and Pharmacology 1992; 36: 123 –126.

27. Skidmore R.L., ed Mosby’s drug guide for nurses. Time Mirror Company, New York: 1996.

28. Sylianco-Wu L., Kallman M., Wilson M., Slikker W. Jr., Hikal A., Ali S., Holson R., Behavioural and neurochemical consequences of perinatal exposure to Type I and Type II pyrethroid formulations. Journal of Neurotoxicology and Teratology 1990; 12: 565.

29. Youngerman-Cole S.R.N., Abnormal vaginal bleeding – Topic Overview ; 2001 WebMD

http://www.nlm.nih.gov/medlineplus/ency/article/003264.htm

30. Arkaravichien W, Kendle K.E., Foetal viability and foetal growth after prolonged uterine contractions induced by progesterone withdrawal in late pregnancy in rats. Journal of Reproduction and Fertility. 1992; 96: 299 – 308.

31. Vermeulen A., Environment, human reproduction, menopause and andropause. Environmental Health Perspective 1993; 101: 91 –100.

32. Roblero L.S., Garavango A.C., Effect of oestradiol-17 and progesterone on oviductal transport and early development of mouse embryos. Journal of Reproduction and Fertility 1979; 57: 91 – 95.
Table 1: Number of rats displaying overt clinical signs of toxicity after oral administration of Icon® or vehicle from days 8 - 14 of pregnancy

| Variable monitored     | Control      | Icon® Treated |
|------------------------|--------------|---------------|
|                        | DW (n=12)    | 63 mg/kg/body wt./day (n=12) | 83 mg/kg/body wt./day (n=12) | 125 mg/kg/body wt./day (n=9) |
| Ataxia                 | 0            | 1             | 1             | 6             |
| Tremor                 | 0            | 0             | 0             | 0             |
| Convulsions            | 0            | 0             | 0             | 0             |
| Piloerection           | 0            | 0             | 0             | 2             |
| Exophthalmia           | 0            | 0             | 0             | 2             |
| Salivation             | 0            | 3 (around mouth) | 12 (around neck) | 12 (whole body) |
| Lacrymation            | 0            | 0             | 0             | 0             |
| Coughing               | 0            | 0             | 0             | 0             |
| Changes in colour of fur | 0            | 0             | 0             | 0             |
| Changes in colour of urine | 0            | 0             | 1 (dark yellow) | 6 (dark yellow) |
| Vaginal bleeding       | 0            | 1             | 3             | 9             |
| Diarrhoea              | 0            | 1             | 3             | 9             |

DW - distilled water
Table 2: Reproductive variables of rats orally administered with Icon® or vehicle from days 8 -14 of pregnancy. Data represented as means ± SEM; Ranges in parentheses

| Variable monitored                      | Control                  | Icon® Treated            |
|----------------------------------------|--------------------------|--------------------------|
|                                        | DW (n=12)                | 63 mg/kg/bodywt./day (n=12) | 83 mg/kg/body wt./day (n=12) | 125 mg/kg/body wt. /day (n=9) |
| Number of corpora lutea                | 12.2 ± 0.4 (10 - 14)     | 12.4 ± 0.4 (11 - 14)     | 11.7 ± 0.6 (8 - 15)          | 12.5 ± 0.7 (10 - 15)          |
| Number of implants                     | 10.1 ± 0.3 (8 - 12)      | 9.2 ± 0.4 (7 - 12)       | 7.2 ± 1.0* (0 - 12)          | 00                            |
| Number of viable implants              | 9.5 ± 0.3 (7 - 12)       | 8.6 ± 0.6 (5 - 12)       | 6.0 ± 1.1* (0 - 11)          | 00                            |
| Width of embryo (mm)                   | 9.9 ± 0.6 (8.5 - 12)     | 10.3 ± 0.2 (9.5 - 11)    | 9.5 ± 0.0 (8 - 10)           | -                             |
| Cranio-sacral diameter of embryo (mm)  | 10.2 ± 0.8 (9 - 13)      | 10.2 ± 0.7 (8 - 12.5)    | 10.1 ± 0.8 (8 - 11.5)        | -                             |
| Gestation length (days)                | 22.5 ± 0.2 (22- 23)      | 22.3 ± 0.2 (22- 23)      | 22.5 ± 0.2 (22 - 23)         | -                             |
| Number of pups born                    | 9.3 ± 0.4 (6 - 12)       | 8.3 ± 0.7 (4 - 12)       | 5.9 ± 1.1* (0 - 11)          | 00                            |
| Number of live pups                    | 9.1 ± 0.4 (6 - 12)       | 7.9 ± 0.7 (4 - 12)       | 5.5 ± 1.0* (0 - 11)          | 00                            |
| Post implantation loss (%)             | 6.2 ± 3.1 (0 - 36.4)     | 7.0 ± 3.7 (0 - 44.4)     | 35.2 ± 11.4* (0 - 100)       | 100**                         |
| Litter index (%)                       | 92.2 ± 3.7 (54.5 - 100)  | 88.7 ± 4.5 (55.6 - 100)  | 64.2 ± 11.2* (0 - 100)       | -                             |
| Gestation index (%)                    | 930                      | 830                      | 553                         | -                             |
| Live birth index (%)                   | 97.5 ±1.8 (77.8 - 100)   | 95.5 ± 2.1 (77.8 - 100)  | 73.0 ± 11.8 (0 - 100)        | -                             |
| Foetal survival Ratio (%)              | 90.4 ± 3.5 (54.5 - 100)  | 84.5 ± 4.6 (55.6 - 100)  | 59.7 ± 10.6* (0 - 100)       | -                             |

As compared with control, *p < 0.05, **p < 0.01, Mann-Whitney U-test, G-test, - means this information can not be calculated as there were no embryos. DW – distilled water treated.
Table 3: Developmental variables of pups, delivered by rats orally administered with Icon® or vehicle from days 8 -14 of pregnancy. Data presented as means ± SEM; Ranges in parentheses.

| Variable monitored | Control DW (n=12) | Icon® Treated 63 mg/kg/bodywt./day (n=12) | Icon® Treated 83 mg/kg/bodywt./day (n=12) | Icon® Treated 125 mg/kg/bodywt./day (n=9) |
|--------------------|------------------|------------------------------------------|-------------------------------------------|-------------------------------------------|
| Body weight (g)    | 5.0 ± 0.1 (4.3 - 6.0) | 5.2 ± 0.2 (4.0 - 6.2) | 5.0 ± 0.1 (4.3 - 5.6) | - |
| Cranial length (mm)| 13.5 ± 0.2 (12.5 - 14.5) | 13.7 ± 0.2 (12.3 - 14.6) | 13.5 ± 0.3 (12.4 - 14.6) | - |
| Cranial diameter (mm) | 10.4 ± 0.2 (9.3 - 12.5) | 9.8 ± 0.2 (8.6 - 11.0) | 9.9 ± 0.2 (9.3 - 10.6) | - |
| Tail length (mm)   | 15.9 ± 0.2 (14.6 - 17.1) | 15.9 ± 0.3 (14.6 - 18) | 15.8 ± 0.3 (14.7 - 17.3) | - |
| Cranio - sacral length (mm) | 40.9 ± 0.4 (38.2 - 43) | 40.0 ± 0.4 (37.1 - 42.2) | 39.7 ± 0.4 (37.9 - 41.6) | - |
| Fur appearance time (Days) | 2.2 ± 0.2 (2 - 3) | 2.2 ± 0.2 (2 - 3) | 2.3 ± 0.2 (2 - 3) | - |
| Eye opening time (Days) | 15.2 ± 0.3 (14 - 16) | 14.8 ± 0.2 (14 - 15) | 15.0 ± 0.3 (14 - 16) | - |

- means this information can not be calculated as there were no pups. DW – distilled water treated.